HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain

Diminished GABAergic and glycinergic inhibition in the spinal dorsal horn contributes significantly to chronic pain of different origins. Accordingly, pharmacological facilitation of GABAergic inhibition by spinal benzodiazepines (BDZs) has been shown to reverse pathological pain in animals as well...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropharmacology 2011-03, Vol.60 (4), p.626-632
Hauptverfasser:	Di Lio, Alessandra, Benke, Dietmar, Besson, Marie, Desmeules, Jules, Daali, Youssef, Wang, Zhi-jian, Edwankar, Rahul, Cook, James M, Zeilhofer, Hanns Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Benzodiazepines - pharmacology Benzodiazepines - therapeutic use Dose-Response Relationship, Drug Flumazenil - pharmacology GABA Modulators - pharmacology GABA-A Receptor Agonists - pharmacology GABA-A Receptor Agonists - therapeutic use Hyperalgesia - drug therapy Hyperalgesia - etiology Imidazoles - pharmacology Imidazoles - therapeutic use Inflammation - drug therapy Inflammation - etiology Mice Motor Activity - drug effects Neuralgia - drug therapy Neuralgia - etiology Neurons - drug effects Neurons - metabolism Pain Measurement - drug effects Receptors, GABA-A - metabolism Sciatic Neuropathy - complications
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!